Basic and Clinical Studies on Cefmenoxime in Pediatric Field

Satoshi Iwata, Yukio Iwasaki, Takefumi Kanemitsu, Hironobu Akita, Masahiro Hotta, Naoya Yamashita, Seiichiro Nanri, Ryo Wakabayashi, Yosiiibumi Kojima, Keisuke Sunakawa, Mitsuru Osano, Yasuo Ichihashi

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)

Abstract

Basic and clinical studies were made on cefmenoxime(CMX)in pediatric field, and the following results were obtained. 1. The antibacterial activity of CMX against clinically isolated and maintained strains was examined. CMX had stronger antibacterial activity than CEZ against Escherichia coli, Salmonella, Klebsiella pneumoniae, Proteus mirabilis, Serratia marcescens and Pseudomonas aeruginosa, but CEZ had stronger antibacterial activity against Staphylococcus aureus. 2. The blood concentrations of CMX, 0.5, 1, 2, 4 and 6 hours after a one-shot intravenous injection of 20mg/kg of CMX were 33.6, 15.1, 4.5, 2.5 and 0.6mcg/ml, respectively, with the half-life of 1.04 hours. 3. The blood concentrations of CMX, 0.5, 1, 2, 4 and 6 hours after a 1-hour intravenous drip infusion of 20 mg/kg of CMX were 32.0, 55.2, 8.4, 4.2 and 1.0 mcg/ml, respectively, with the half-lite of 0.96 hour. 4. A complete or partial clinical response to therapy with CMX was obtained in all 10 children with infectious diseases. 5. Bacteriological examination made on 3 patients showed that all bacteria had been eradicated, and that therapy was effective. The bacteria were E. coli in 2 patients and Proteus mirabilis in 1 patient. 6. The side effects produced were neutropenia, eosinophilia and skin eruption in 1 patient, and diarrhea in 1 patient.

Original languageEnglish
Pages (from-to)2440-2449
Number of pages10
Journalthe japanese journal of antibiotics
Volume35
Issue number10
DOIs
Publication statusPublished - 1982 Jan 1

ASJC Scopus subject areas

  • Microbiology (medical)
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Basic and Clinical Studies on Cefmenoxime in Pediatric Field'. Together they form a unique fingerprint.

Cite this